JP2021097695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021097695A5 JP2021097695A5 JP2021036823A JP2021036823A JP2021097695A5 JP 2021097695 A5 JP2021097695 A5 JP 2021097695A5 JP 2021036823 A JP2021036823 A JP 2021036823A JP 2021036823 A JP2021036823 A JP 2021036823A JP 2021097695 A5 JP2021097695 A5 JP 2021097695A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- mutane
- immunoglobulin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022152103A JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166184 | 2015-05-04 | ||
| EP15166184.0 | 2015-05-04 | ||
| JP2017557299A JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557299A Division JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152103A Division JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021097695A JP2021097695A (ja) | 2021-07-01 |
| JP2021097695A5 true JP2021097695A5 (enExample) | 2021-09-16 |
| JP7149363B2 JP7149363B2 (ja) | 2022-10-06 |
Family
ID=53054879
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557299A Active JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
| JP2021036823A Active JP7149363B2 (ja) | 2015-05-04 | 2021-03-09 | Ｃｄ１３７に特異的なタンパク質 |
| JP2022152103A Active JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557299A Active JP6884708B2 (ja) | 2015-05-04 | 2016-05-04 | Ｃｄ１３７に特異的なタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152103A Active JP7477905B2 (ja) | 2015-05-04 | 2022-09-26 | Ｃｄ１３７に特異的なタンパク質 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11261221B2 (enExample) |
| EP (2) | EP4177262A1 (enExample) |
| JP (3) | JP6884708B2 (enExample) |
| KR (1) | KR102734408B1 (enExample) |
| CN (2) | CN107820500B (enExample) |
| AU (1) | AU2016258952C1 (enExample) |
| CA (1) | CA2980839C (enExample) |
| CL (1) | CL2017002767A1 (enExample) |
| DK (1) | DK3292137T3 (enExample) |
| ES (1) | ES2932425T3 (enExample) |
| IL (1) | IL254516B (enExample) |
| MX (1) | MX2017014082A (enExample) |
| NZ (1) | NZ736560A (enExample) |
| PH (1) | PH12017501583B1 (enExample) |
| RU (1) | RU2736312C2 (enExample) |
| SG (1) | SG11201708339QA (enExample) |
| WO (1) | WO2016177762A1 (enExample) |
| ZA (1) | ZA201705960B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549968B2 (en) | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
| CA2891557A1 (en) | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| CN113621050A (zh) | 2014-05-22 | 2021-11-09 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| SG10201906859PA (en) | 2015-01-28 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| FI3298030T3 (fi) | 2015-05-18 | 2023-02-22 | Pieris Pharmaceuticals Gmbh | Syöpää ehkäisevä fuusiopolypeptidi |
| CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| SG11201803732PA (en) | 2015-11-30 | 2018-06-28 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CN112004535A (zh) | 2018-03-26 | 2020-11-27 | 4Sc股份公司 | 用于癌症疗法的包括hdac抑制剂和cd137激动剂的组合 |
| CN112789294A (zh) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
| AU2019315703A1 (en) * | 2018-07-31 | 2020-12-10 | Les Laboratoires Servier | Novel fusion protein specific for CD137 and PD-L1 |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| US12486330B2 (en) * | 2019-02-26 | 2025-12-02 | Pieris Pharmaceuticals Gmbh | Fusion proteins specific for CD137 and GPC3 |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| EP3952996A1 (en) | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
| JP2023502876A (ja) | 2019-11-04 | 2023-01-26 | ピエリス ファーマシューティカルズ ゲーエムベーハー | がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 |
| CN116249709A (zh) | 2020-06-05 | 2023-06-09 | 皮里斯制药有限公司 | 靶向4-1bb的多聚体免疫调节剂 |
| EP4213946A1 (en) | 2020-09-18 | 2023-07-26 | Pieris Pharmaceuticals GmbH | Biomarker methods and uses |
| CN117355319A (zh) | 2021-03-23 | 2024-01-05 | 皮里斯制药有限责任公司 | 用于癌症治疗的her2/4-1bb双特异性融合蛋白 |
| WO2022200478A1 (en) | 2021-03-24 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor |
| WO2023118497A1 (en) | 2021-12-22 | 2023-06-29 | Pieris Pharmaceuticals Gmbh | Novel il-18 variants |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| TW202428603A (zh) | 2022-09-21 | 2024-07-16 | 美商思進公司 | 新穎的cd137及cd228特異性融合蛋白 |
| WO2025175123A1 (en) | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3779221D1 (de) | 1986-08-19 | 1992-06-25 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| WO1995031479A1 (en) | 1994-05-18 | 1995-11-23 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| AU2007280398B2 (en) | 2006-08-01 | 2012-05-10 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| CA2702590A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| US9549968B2 (en) | 2009-12-07 | 2017-01-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target |
| CA2808392C (en) * | 2010-08-16 | 2020-03-10 | Pieris Ag | Binding proteins for hepcidin |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| CA2905186A1 (en) | 2013-03-14 | 2014-09-18 | Daiichi Sankyo Co., Ltd | Novel binding proteins for pcsk9 |
| CA2891557A1 (en) * | 2013-03-26 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| SG10201906859PA (en) | 2015-01-28 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| AR103714A1 (es) | 2015-02-18 | 2017-05-31 | Sanofi Sa | Proteínas específicas para pioverdina y pioquelina |
| US11261221B2 (en) | 2015-05-04 | 2022-03-01 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| CN107787327B (zh) | 2015-05-18 | 2022-02-08 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| FI3298030T3 (fi) * | 2015-05-18 | 2023-02-22 | Pieris Pharmaceuticals Gmbh | Syöpää ehkäisevä fuusiopolypeptidi |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
-
2016
- 2016-05-04 US US15/571,611 patent/US11261221B2/en active Active
- 2016-05-04 DK DK16721149.9T patent/DK3292137T3/da active
- 2016-05-04 MX MX2017014082A patent/MX2017014082A/es unknown
- 2016-05-04 EP EP22193830.1A patent/EP4177262A1/en active Pending
- 2016-05-04 RU RU2017135599A patent/RU2736312C2/ru active
- 2016-05-04 JP JP2017557299A patent/JP6884708B2/ja active Active
- 2016-05-04 NZ NZ736560A patent/NZ736560A/en unknown
- 2016-05-04 ES ES16721149T patent/ES2932425T3/es active Active
- 2016-05-04 KR KR1020177034948A patent/KR102734408B1/ko active Active
- 2016-05-04 WO PCT/EP2016/059959 patent/WO2016177762A1/en not_active Ceased
- 2016-05-04 CN CN201680025274.3A patent/CN107820500B/zh active Active
- 2016-05-04 AU AU2016258952A patent/AU2016258952C1/en active Active
- 2016-05-04 PH PH1/2017/501583A patent/PH12017501583B1/en unknown
- 2016-05-04 EP EP16721149.9A patent/EP3292137B1/en active Active
- 2016-05-04 SG SG11201708339QA patent/SG11201708339QA/en unknown
- 2016-05-04 CN CN202210118268.XA patent/CN114573680A/zh active Pending
- 2016-05-04 CA CA2980839A patent/CA2980839C/en active Active
-
2017
- 2017-09-01 ZA ZA2017/05960A patent/ZA201705960B/en unknown
- 2017-09-14 IL IL254516A patent/IL254516B/en unknown
- 2017-11-02 CL CL2017002767A patent/CL2017002767A1/es unknown
-
2021
- 2021-03-09 JP JP2021036823A patent/JP7149363B2/ja active Active
-
2022
- 2022-01-19 US US17/579,392 patent/US12195503B2/en active Active
- 2022-09-26 JP JP2022152103A patent/JP7477905B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021097695A5 (enExample) | ||
| JP7181612B2 (ja) | アルカリ安定性免疫グロブリン結合タンパク質 | |
| JP6181145B2 (ja) | 改善された特異性を有する新規免疫グロブリン結合タンパク質 | |
| Piers et al. | Recombinant DNA procedures for producing small antimicrobial cationic peptides in bacteria | |
| CA2135208C (en) | Immunoglobulin binding proteins derived from l protein and their uses | |
| JP5229888B2 (ja) | 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤 | |
| JP2021007390A5 (enExample) | ||
| Han et al. | Assessment of prokaryotic collagen-like sequences derived from streptococcal Scl1 and Scl2 proteins as a source of recombinant GXY polymers | |
| JPWO2012165544A1 (ja) | 酸性域での親和性が低下したプロテインａ変異型タンパク質及び抗体捕捉剤 | |
| Gallizia et al. | Production of a soluble and functional recombinant streptavidin inescherichia coli | |
| JP2008532549A (ja) | 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素 | |
| JP2003534013A5 (enExample) | ||
| JPWO2015050153A1 (ja) | 免疫グロブリンＧ（ＩｇＧ）のＦｃ部分を有するタンパク質に対するアフィニティを有する複数のドメイン間をリンカーで結合させて成るタンパク質 | |
| JPWO2019144095A5 (enExample) | ||
| JP2019163270A (ja) | 親和性タンパク質及びその使用 | |
| JP2566325B2 (ja) | 免疫複合体の選択的除去 | |
| Hass et al. | Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use in epitope mapping | |
| CA2096953A1 (en) | Immunoglobulin-binding proteins and recombinant dna molecules coding therefor | |
| JPWO2021191447A5 (enExample) | ||
| JP2004500055A5 (enExample) | ||
| JPWO2022129560A5 (enExample) | ||
| JPWO2023112028A5 (enExample) | ||
| CN109504667B (zh) | Irak-m多克隆抗体及其制备方法 | |
| Li et al. | Soluble expression and affinity purification of functional domain of human acetylcholine receptor α-subunit by the modulation of maltose binding protein | |
| Popplewell et al. | Synthesis and mutagenesis of an IgG-binding protein based upon protein A of Staphylococcus aureus |